Vertex Pharmaceuticals is expected to report Q3 2026 revenue of $3.42 billion and adjusted EPS of $4.36, with its current stock price of $529.69 trading approximately 8% below the average analyst target of $574.11.
Investors are primarily focused on the company's diversification efforts, specifically the commercial traction of its first non-cystic fibrosis launches, JOURNAVX and CASGEVY, as they aim for a $500 million non-CF revenue target in 2026.
While the core cystic fibrosis franchise remains dominant, the recently launched next-generation therapy ALYFTREK is expected to show continued growth after a strong first-half performance. Analysts are also watching for updates on the renal and pain pipelines as the company invests heavily in its scaling commercial infrastructure.